is a difficult-to-treat, multidrug-resistant human pathogen. Relebactam has been shown to inhibit β-lactamase (BLA) and increase the activity of imipenem and amoxicillin. We present two cases of lung infection due to , one caused by subsp and the other by subsp. Both strains showed moderate sensitivity to imipenem, and the second strain was also resistant to macrolides. A multidrug antibiotic regimen was administered in both cases, which included imipenem/cilastatin/relebactam adjusted to the estimated glomerular filtration rate (eGFR) and amoxicillin for three months. The regimen was well tolerated and both patients improved both clinically and radiologically after the first phase of treatment. The results of our patients indicate that the combination of imipenem/cilastatin/relebactam and amoxicillin could be used in the future in difficult infections by .

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11338295PMC
http://dx.doi.org/10.7759/cureus.65112DOI Listing

Publication Analysis

Top Keywords

antibiotic regimen
8
lung infection
8
combination imipenem-cilastatin-relebactam
4
amoxicillin
4
imipenem-cilastatin-relebactam amoxicillin
4
amoxicillin antibiotic
4
regimen cases
4
cases mycobacterium
4
mycobacterium abscessus
4
abscessus lung
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!